新诊断胶质母细胞瘤放化疗时机:县医疗与管理式医疗模式比较
该回顾性研究纳入2004至2019年加州圣贝纳迪诺县2家医院57例新诊断胶质母细胞瘤患者,比较县医疗与管理式医疗(HMO)模式下辅助治疗启动时间。HMO组化疗和放疗启动均显著早于县医疗组,但两组复发时间和死亡时间无显著差异。
要点
- HMO组化疗启动中位时间显著早于县医疗组(41±30天 vs 77±68天,P=0.050)。
- HMO组放疗启动中位时间显著早于县医疗组(46±34天 vs 85±76天,P=0.036)。
- 两组复发时间和死亡时间差异无统计学意义。
核心结论
- 县医院与管理式医疗组织之间,胶质母细胞瘤患者辅助治疗启动时间存在统计学显著差异。
研究设计与样本
- 回顾性分析,纳入2004至2019年加州圣贝纳迪诺县2家医院新诊断胶质母细胞瘤患者57例。
主要发现
- HMO组化疗启动时间为41±30天,县医疗组为77±68天(P=0.050)。
- HMO组放疗启动时间为46±34天,县医疗组为85±76天(P=0.036)。
- 同时接受化疗和放疗者中,放疗时间差异不再显著(P=0.060)。
- HMO组与县医疗组复发时间分别为309±263天和212±180天(P=0.379)。
- HMO组与县医疗组死亡时间分别为412±285天和343±304天(P=0.334)。
临床怎么用
- 县医疗模式可参考HMO模式优化 care coordination,以缩短辅助治疗启动延迟。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Glioblastoma multiforme (GBM) is a primary brain malignancy with significant morbidity and mortality. The current standard of treatment for GBM is surgery followed by radiotherapy and temozolomide. Despite an established treatment protocol, there exists heterogeneity in outcomes due to patients not receiving all treatments. We analyzed patients in different health care models to investigate this heterogeneity. METHODS: A retrospective analysis was performed at 2 hospitals in San Bernardino County, California, for patients with newly diagnosed GBM from 2004 to 2019. Patients younger than 18 years of age, with history of low-grade glioma, who had undergone prior treatment, and those lost to follow-up were excluded. RESULTS: A total of 57 patients were included in our study. Chemotherapy was started at 41 ± 30 and 77 ± 68 days in the health maintenance organization (HMO) and county model, respectively (P = 0.050); radiation therapy was started at 46 ± 34 and 85 ± 76 days in the HMO and county models, respectively (P = 0.036). In individuals who underwent both chemotherapy and radiation therapy (XRT), the difference in time to XRT was no longer significant (P = 0.060). Recurrence time was 309 ± 263 and 212 ± 180 days in the HMO and county groups, respectively (P = 0.379). The time to death was 412 ± 285 and 343 ± 304 days for HMO and county models, respectively (P = 0.334). CONCLUSIONS: Our study demonstrates a statistically significant difference in time to adjuvant therapies between patients within a county hospital and a managed health care organization. This information has the potential to inform future policies and care coordination for patients within the county model.
引用
- Toor H, Savla P, Podkovik S, et al. Timing of Chemoradiation in Newly Diagnosed Glioblastoma: Comparative Analysis Between County and Managed Care Health Care Models. World Neurosurg. 2021. PMID: 33476782. doi:10.1016/j.wneu.2021.01.023
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。